使用抗CD20抗体利妥昔单抗成功辅助治疗顽固性黏膜类天疱疮。
Successful adjuvant treatment of recalcitrant mucous membrane pemphigoid with anti-CD20 antibody rituximab.
作者信息
Taverna Josephine A, Lerner Adam, Bhawan Jag, Demierre Marie-France
机构信息
Skin Oncology Program, Department of Dermatology, Boston University School of Medicine, MA 02118, USA.
出版信息
J Drugs Dermatol. 2007 Jul;6(7):731-2.
PMID:17763598
Abstract
Rituximab is a humanized monoclonal antibody directed against CD20-positive B cells and originally developed for the treatment of non-Hodgkins lymphoma. We report a case of severe mucous membrane pemphigoid responsive to rituximab infusions. The clinical presentation, etiology, and management options for mucous membrane pemphigoid are also discussed.
摘要
利妥昔单抗是一种针对CD20阳性B细胞的人源化单克隆抗体，最初用于治疗非霍奇金淋巴瘤。我们报告了1例对利妥昔单抗输注有反应的严重黏膜类天疱疮病例。还讨论了黏膜类天疱疮的临床表现、病因及治疗选择。
Zotero 插件